NCT04575779View on ClinicalTrials.gov

Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

July 10, 2018

Primary Completion Date

April 4, 2021

Study Completion Date

May 30, 2022

Conditions
Allogenic Bone Marrow Transplantation
Interventions
DRUG

Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h

To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.

Trial Locations (1)

Unknown

Shaymaa Mohammed Mohammed Youssef El-Awady, Cairo

All Listed Sponsors
lead

Shaymaa Mohammed El-Awady

OTHER

NCT04575779 - Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter